|  |  |
| --- | --- |
|  |  |

**BRIDGEBIO AND BOSTON CHILDREN’S HOSPITAL**

**CALL FOR PROPOSALS 2021**

# Background

Boston Children’s Hospital, a premiere research and clinical institution, and BridgeBio, a biotech company targeting genetic disease at the source, have entered into a collaboration to fund genetically-targeted translational research.

BridgeBio was founded in 2015 and has in-licensed over 15 therapeutics from academia, with two already in Phase 3 clinical trials. Each drug is housed in its own new company (NewCo), to ensure an independent team is overseeing that drug’s success. BridgeBio is generally agnostic to disease area and therapeutic modality, with the one unifying property across our portfolio being that our drugs must be targeting a genetic alteration in disease, such as a mutated protein.

The goal of this collaboration is to advance a therapeutic idea to the point where we can build a NewCo around it. This generally means we work together to plan experiments over a 1-2 year period, ultimately toward achieving proof of efficacy in an animal model of disease. Once we have started a NewCo, we commit to funding the NewCo through its entirety–until patients are benefitting from the drug.

Our drug engine depends on alliances with elite research institutions like BCH. Through our alliance, we aim to award in-scope projects at least $75k to $750k, with the option for increased funding later if we are hitting our scientific milestones.

# Program Eligibility

## 1. Applicants

* Any principal investigator performing research at and employed by BCH
* There are no restrictions on the number of proposals one applicant can submit

**Areas of interest**

* Any disease with at least roughly 5,000 patients in the US + EU with a known mutation causing the disease
* Any approach that directly targets or compensates for the underlying genetic defect (e.g., directly inhibits a gain-of-function protein, replaces a loss-of-function protein)
* Any therapeutic modality for which there is at least one approved drug

**Examples of research eligible for funding (not comprehensive)**

* Earliest phase eligible: A new mutation has been identified with evidence it is a driver of disease, and the investigator has a screening assay for drugs that target the mutated protein
* Investigator has identified a lead drug that still needs optimization before consideration as a development candidate
* Investigator has a development candidate that requires funding for IND-enabling studies

**Examples of research NOT eligible for funding (not comprehensive)**

* Any novel modalities or combinations of modalities that have not been tested clinically as therapeutic agents before
* Funding for basic research to identify new mechanisms of disease
* Funding for repurposing approved drugs (unless there is clear path to novel IP)

# Submission Process

## Pre-proposals

Pre-proposals must be **non-confidential** and limited to **two pages** (excluding bio-sketch) prepared using the template provided. **Completed pre-proposals are due on March 12th, 2021**. Selected applicants will be invited to submit full proposals.

## Full proposals

Finalists invited to submit full proposals will be notified by **April 30th, 2021**. The award decisions will be made by a Joint Steering Committee composed of BridgeBio and Boston Children’s representatives. **Funding is expected to begin in September 2021**.

## Application Timeline

|  |  |
| --- | --- |
| **Event** | **Date** |
| Pre-proposal due to TIDO (*TIDO.alliances@childrens.harvard.edu*) | **March 12th, 2021** |
| Announcement of selected pre-proposals invited to full proposal stage.  | April 30th, 2021  |
| Full proposal due to TIDO  | June 11th, 2021 |
| Notification of selected projects for funding  | August 13th, 2021 |
| Initiation of funding | September 2021 |

# For More Information:

Boston Children’s Technology & Innovation Development Office TIDO.alliances@childrens.harvard.edu or shreya.sawant@childrens.harvard.edu

BridgeBio : Head of Strategic Alliances, Eric Gomez, at eg@bridgebio.com